Oregon Public Employees Retirement Fund Purchases 8,019 Shares of Becton, Dickinson and Company $BDX

Oregon Public Employees Retirement Fund grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 32.3% in the third quarter, Holdings Channel reports. The fund owned 32,811 shares of the medical instruments supplier’s stock after buying an additional 8,019 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Becton, Dickinson and Company were worth $6,141,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of BDX. Vanguard Group Inc. raised its stake in Becton, Dickinson and Company by 15.4% during the second quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock valued at $5,565,182,000 after purchasing an additional 4,305,947 shares in the last quarter. Norges Bank bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter worth about $653,377,000. First Eagle Investment Management LLC raised its position in shares of Becton, Dickinson and Company by 59.2% during the 2nd quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock valued at $1,513,421,000 after buying an additional 3,268,478 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Becton, Dickinson and Company by 24.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 8,514,446 shares of the medical instruments supplier’s stock valued at $1,466,613,000 after buying an additional 1,670,590 shares in the last quarter. Finally, Laurel Wealth Advisors LLC lifted its holdings in shares of Becton, Dickinson and Company by 16,974.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 1,579,386 shares of the medical instruments supplier’s stock valued at $272,049,000 after acquiring an additional 1,570,136 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 629 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $196.03, for a total value of $123,302.87. Following the completion of the sale, the executive vice president owned 13,105 shares in the company, valued at approximately $2,568,973.15. The trade was a 4.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director owned 35,816 shares in the company, valued at $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,052 shares of company stock worth $201,235 over the last 90 days. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $202.78 on Friday. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. The stock’s fifty day moving average is $193.11 and its two-hundred day moving average is $188.24. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The company has a market capitalization of $57.77 billion, a PE ratio of 34.78, a price-to-earnings-growth ratio of 2.24 and a beta of 0.23.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were given a $1.05 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend was Monday, December 8th. This represents a $4.20 annualized dividend and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio is presently 72.04%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BDX. Stifel Nicolaus upped their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday. Piper Sandler decreased their price target on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, November 7th. Royal Bank Of Canada raised their price target on Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a research report on Wednesday, December 17th. Bank of America boosted their price objective on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research report on Monday, January 5th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and an average target price of $207.64.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.